Your browser is no longer supported. Please, upgrade your browser.
KPTI [NASD]
Karyopharm Therapeutics Inc.
Index- P/E- EPS (ttm)-2.73 Insider Own2.70% Shs Outstand73.74M Perf Week-19.35%
Market Cap824.87M Forward P/E- EPS next Y-0.93 Insider Trans-13.19% Shs Float66.49M Perf Month-24.04%
Income-196.30M PEG- EPS next Q-0.68 Inst Own88.50% Short Float23.68% Perf Quarter-33.27%
Sales108.10M P/S7.63 EPS this Y15.40% Inst Trans-4.88% Short Ratio5.30 Perf Half Y-27.09%
Book/sh0.69 P/B16.07 EPS next Y58.50% ROA-54.30% Target Price- Perf Year-55.68%
Cash/sh3.35 P/C3.31 EPS next 5Y- ROE-182.50% 52W Range10.57 - 26.30 Perf YTD-28.36%
Dividend- P/FCF- EPS past 5Y3.90% ROI-71.30% 52W High-57.83% Beta0.43
Dividend %- Quick Ratio4.50 Sales past 5Y236.60% Gross Margin97.50% 52W Low4.92% ATR0.84
Employees432 Current Ratio4.60 Sales Q/Q93.90% Oper. Margin- RSI (14)22.38 Volatility7.80% 5.77%
OptionableYes Debt/Eq3.78 EPS Q/Q22.60% Profit Margin- Rel Volume0.55 Prev Close11.63
ShortableYes LT Debt/Eq3.78 EarningsFeb 11 BMO Payout- Avg Volume2.97M Price11.09
Recom1.70 SMA20-23.77% SMA50-27.23% SMA200-31.09% Volume1,629,058 Change-4.64%
Jul-02-20Initiated Morgan Stanley Overweight $34
Mar-04-20Initiated Barclays Overweight $30
Jan-17-20Downgrade Wedbush Outperform → Neutral
Jul-23-19Upgrade JP Morgan Neutral → Overweight $8 → $16
Jul-05-19Reiterated Robert W. Baird Outperform $15 → $25
Jul-05-19Reiterated H.C. Wainwright Buy $29 → $32
Mar-01-19Downgrade JP Morgan Overweight → Neutral $21 → $7
Feb-28-19Reiterated BofA/Merrill Underperform $15 → $5
Feb-27-19Downgrade BofA/Merrill Neutral → Underperform $15 → $5
Jan-03-19Upgrade BofA/Merrill Underperform → Neutral
Dec-03-18Initiated B. Riley FBR Buy $23
Nov-09-18Upgrade Wedbush Neutral → Outperform $19
May-24-18Downgrade Wedbush Outperform → Neutral $20 → $19
Apr-02-18Resumed Leerink Partners Outperform $19
Nov-15-17Resumed H.C. Wainwright Buy $23
Sep-15-17Initiated RBC Capital Mkts Outperform $14
Sep-08-16Reiterated H.C. Wainwright Buy $15 → $16
Aug-30-16Upgrade Jefferies Hold → Buy
Aug-18-16Initiated H.C. Wainwright Buy $15
Jun-28-16Initiated Robert W. Baird Outperform $16
Mar-01-21 04:05PM  
Feb-17-21 04:05PM  
Feb-13-21 02:04AM  
Feb-12-21 10:50PM  
02:58AM  
Feb-11-21 02:30PM  
09:46AM  
08:45AM  
07:26AM  
07:00AM  
06:30AM  
Feb-04-21 09:00AM  
07:00AM  
Feb-01-21 04:05PM  
Jan-29-21 10:50PM  
08:38AM  
Jan-11-21 08:00AM  
Jan-04-21 04:05PM  
07:00AM  
Jan-03-21 07:00PM  
Dec-21-20 09:29AM  
Dec-20-20 07:00PM  
Dec-18-20 10:50PM  
10:44PM  
11:30AM  
Dec-15-20 07:00AM  
Dec-14-20 02:14AM  
Dec-11-20 11:08AM  
Dec-07-20 04:05PM  
01:30PM  
Dec-01-20 04:05PM  
07:00AM  
Nov-30-20 03:48AM  
Nov-25-20 07:35AM  
07:00AM  
Nov-20-20 10:30AM  
Nov-12-20 07:06PM  
Nov-10-20 07:00AM  
Nov-04-20 01:16PM  
Nov-03-20 08:00AM  
07:38AM  
Nov-02-20 11:31PM  
05:55PM  
04:41PM  
04:05PM  
04:01PM  
02:30PM  
Oct-29-20 11:35AM  
Oct-26-20 12:31PM  
07:00AM  
Oct-20-20 10:00AM  
Oct-19-20 04:01PM  
Oct-06-20 06:44PM  
08:00AM  
Oct-01-20 04:05PM  
Sep-14-20 10:27AM  
09:42AM  
Sep-11-20 08:35AM  
Sep-02-20 07:00AM  
Sep-01-20 04:05PM  
Aug-31-20 07:00AM  
Aug-21-20 08:00AM  
Aug-10-20 08:00AM  
Aug-04-20 10:01PM  
08:25AM  
07:00AM  
Aug-03-20 04:05PM  
Jul-29-20 02:32PM  
09:40AM  
Jul-28-20 12:33PM  
07:00AM  
Jul-27-20 08:32PM  
Jul-20-20 07:00AM  
Jul-17-20 07:00AM  
Jul-14-20 07:00AM  
Jul-01-20 04:05PM  
Jun-24-20 07:00AM  
Jun-23-20 11:50AM  
Jun-22-20 11:25AM  
Jun-21-20 02:53PM  
Jun-18-20 03:34PM  
Jun-12-20 03:58PM  
07:00AM  
Jun-10-20 10:04AM  
Jun-09-20 09:00AM  
Jun-03-20 08:32AM  
Jun-01-20 04:05PM  
May-29-20 07:22AM  
May-28-20 04:05PM  
May-26-20 04:05PM  
07:00AM  
May-20-20 08:00AM  
May-13-20 08:00AM  
May-12-20 07:00AM  
May-06-20 08:07AM  
May-05-20 07:51PM  
05:30PM  
10:45AM  
08:11AM  
07:00AM  
Karyopharm Therapeutics Inc., a pharmaceutical company, engages in the discovery, development, and commercialization of various drugs directed against nuclear export and related targets for the treatment of cancer and other diseases. The company is developing small molecule selective inhibitor of nuclear export (SINE) compounds that inhibit the nuclear export protein exportin 1. Its lead compound is XPOVIO (selinexor) tablets for the treatment of patients with heavily pretreated multiple myeloma and diffuse large B-cell lymphoma (DLBCL). The company develops BOSTON, which is in Phase 3 clinical trial for the treatment of patients with multiple myeloma; STORM, which is in Phase 2b single-arm clinical trial for evaluating oral selinexor in combination with standard, low-dose dexamethasone in heavily pretreated patients, relapsed or refractory myeloma; STOMP, which is in Phase 1b/2 multi-arm clinical trial for the treatment of low-dose dexamethasone plus standard therapies, including Velcade, Kyprolis, Revlimid, and Pomalyst or Darzalex; and SADAL, which is in Phase 2b clinical trial for the treatment of patients with relapsed or refractory DLBCL. It also develops SEAL, which is in Phase 3 clinical trial for the treartment of liposarcoma; SIENDO, which is in Phase 3 clinical trial for treatment of endometrial cancer; and KING, which is in Phase 2 for the treatment of glioblastoma multiforme brain tumor. In addition, the company has various investigational programs in clinical or preclinical development, such as Eltanexor (KPT-8602), KPT-9274, and Verdinexor (KPT-335). The company has collaboration agreement with Curadev Pharma Pvt Ltd to identify and co-develop novel small molecules against various biological targets for the treatment of cancer; and a cooperative research and development agreement with the National Cancer Institute for cancer therapy evaluation program. Karyopharm Therapeutics Inc. was incorporated in 2008 and is headquartered in Newton, Massachusetts.
Insider Trading Relationship Date Transaction Cost #Shares Value ($) #Shares Total SEC Form 4
Frenkel RanEVP, Chief Dev. OfficerFeb 18Sale14.832,88742,81846,126Feb 22 08:11 PM
Shah JatinEVP, Chief Medical OfficerFeb 18Sale14.831,18617,59051,791Feb 22 08:12 PM
Shacham SharonPresident & CSOFeb 18Sale14.839,495140,822575,126Feb 22 08:10 PM
Shacham SharonPresident & CSOFeb 18Sale14.839,495140,822776,452Feb 22 08:10 PM
Kauffman MichaelChief Executive OfficerFeb 18Sale14.839,495140,822776,452Feb 22 08:09 PM
Kauffman MichaelChief Executive OfficerFeb 18Sale14.839,495140,822575,126Feb 22 08:09 PM
Lewis TanyaEVP, Chief Reg. AffairsFeb 11Sale15.522,04631,7524,143Feb 17 06:49 PM
Shah JatinEVP, Chief Medical OfficerFeb 11Sale15.521,74827,12748,127Feb 17 06:48 PM
Frenkel RanEVP, Chief Dev. OfficerFeb 11Sale15.522,04631,75239,338Feb 17 06:47 PM
Shacham SharonPresident & CSOFeb 11Sale15.526,601102,441562,821Feb 17 06:45 PM
Shacham SharonPresident & CSOFeb 11Sale15.526,642103,077764,147Feb 17 06:45 PM
Mason MichaelSVP, CFO & TreasurerFeb 11Sale15.522,85844,3545,292Feb 17 06:46 PM
Kauffman MichaelChief Executive OfficerFeb 11Sale15.526,642103,077764,147Feb 17 06:44 PM
Kauffman MichaelChief Executive OfficerFeb 11Sale15.526,601102,441562,821Feb 17 06:44 PM
Mirza Mansoor RazaDirectorDec 18Option Exercise5.435,00027,1505,000Dec 22 06:16 PM
Mirza Mansoor RazaDirectorDec 18Sale18.005,00090,0000Dec 22 06:16 PM
Mirza Mansoor RazaDirectorDec 07Option Exercise5.4320,000108,60020,000Dec 08 05:14 PM
Mirza Mansoor RazaDirectorDec 07Sale16.0720,000321,3830Dec 08 05:14 PM
Primiano Christopher BrettEVP, CBO, GC & SecretaryDec 01Option Exercise10.42137,0611,428,75182,647Dec 03 05:17 PM
Primiano Christopher BrettEVP, CBO, GC & SecretaryDec 01Sale17.53137,0612,402,2274,523Dec 03 05:17 PM
Primiano Christopher BrettEVP, CBO, GC & SecretaryNov 02Sale14.9277211,5184,523Nov 04 04:09 PM
Lewis TanyaEVP,Chief Reg.&Quality OfficerOct 30Sale15.582263,521539Nov 04 08:18 PM
Primiano Christopher BrettEVP, CBO, GC & SecretaryOct 13Option Exercise9.2339,271362,53743,199Oct 14 06:00 PM
Primiano Christopher BrettEVP, CBO, GC & SecretaryOct 13Sale16.8639,271661,9694,649Oct 14 06:00 PM
Shacham SharonPresident & CSOOct 12Option Exercise0.037,500248763,989Oct 14 05:54 PM
Kauffman MichaelChief Executive OfficerOct 12Option Exercise0.037,500248763,989Oct 14 05:56 PM
Kauffman MichaelChief Executive OfficerOct 12Sale14.897,500111,682756,489Oct 14 05:56 PM
Shacham SharonPresident & CSOOct 12Sale14.897,500111,682756,489Oct 14 05:54 PM
Primiano Christopher BrettEVP, CBO, GC & SecretarySep 08Option Exercise6.5410,05465,75314,703Sep 10 08:49 AM
Primiano Christopher BrettEVP, CBO, GC & SecretarySep 08Sale14.9810,054150,6094,649Sep 10 08:49 AM
DEMAREE JOHNChief Commercial OfficerAug 26Buy14.547,500109,0127,500Aug 27 04:00 PM
Shacham SharonPresident & CSOAug 17Option Exercise0.031,47749757,966Aug 18 06:05 PM
Kauffman MichaelChief Executive OfficerAug 17Option Exercise0.031,47749757,966Aug 18 06:07 PM
Kauffman MichaelChief Executive OfficerAug 17Sale15.001,47722,155756,489Aug 18 06:07 PM
Shacham SharonPresident & CSOAug 17Sale15.001,47722,155756,489Aug 18 06:05 PM
Kauffman MichaelChief Executive OfficerJul 15Option Exercise0.037,500248763,989Jul 17 04:26 PM
Shacham SharonPresident & CSOJul 15Option Exercise0.037,500248763,989Jul 17 04:24 PM
Shah JatinEVP, Chief Medical OfficerJul 15Sale19.4658911,46243,229Nov 04 08:16 PM
Shacham SharonPresident & CSOJul 15Sale19.437,500145,723756,489Jul 17 04:24 PM
Kauffman MichaelChief Executive OfficerJul 15Sale19.437,500145,723756,489Jul 17 04:26 PM
Shacham SharonPresident & CSOJul 10Option Exercise4.757,50035,640562,622Jul 13 06:43 PM
Kauffman MichaelChief Executive OfficerJul 10Option Exercise4.757,50035,640562,622Jul 13 06:45 PM
Kauffman MichaelChief Executive OfficerJul 10Sale19.017,500142,539555,122Jul 13 06:45 PM
Shacham SharonPresident & CSOJul 10Sale19.017,500142,539555,122Jul 13 06:43 PM
Shacham SharonPresident & CSOJul 09Option Exercise4.757,50035,640763,989Jul 13 06:43 PM
Kauffman MichaelChief Executive OfficerJul 09Option Exercise4.757,50035,640763,989Jul 13 06:45 PM
Kauffman MichaelChief Executive OfficerJul 09Sale19.537,500146,487756,489Jul 13 06:45 PM
Shacham SharonPresident & CSOJul 09Sale19.537,500146,487756,489Jul 13 06:43 PM
Kauffman MichaelChief Executive OfficerJun 22Option Exercise0.037,500248763,989Jun 24 04:07 PM
Shacham SharonPresident & CSOJun 22Option Exercise0.037,500248763,989Jun 24 04:05 PM
Kauffman MichaelChief Executive OfficerJun 22Sale20.007,500150,000756,489Jun 24 04:07 PM
Shacham SharonPresident & CSOJun 22Sale20.007,500150,000756,489Jun 24 04:05 PM
Shacham SharonPresident & CSOJun 15Option Exercise0.037,500248763,632Jun 17 04:05 PM
Kauffman MichaelChief Executive OfficerJun 15Option Exercise0.037,500248763,632Jun 17 04:07 PM
Shacham SharonPresident & CSOJun 15Sale16.377,500122,779756,489Jun 17 04:05 PM
Kauffman MichaelChief Executive OfficerJun 15Sale16.377,500122,779756,489Jun 17 04:07 PM
Shacham SharonPresident & CSOJun 10Option Exercise4.757,50035,640562,622Jun 11 04:36 PM
Kauffman MichaelChief Executive OfficerJun 10Option Exercise4.757,50035,640562,622Jun 11 04:39 PM
Kauffman MichaelChief Executive OfficerJun 10Sale18.137,500135,944555,122Jun 11 04:39 PM
Shacham SharonPresident & CSOJun 10Sale18.137,500135,944555,122Jun 11 04:36 PM
Shacham SharonPresident & CSOJun 09Option Exercise4.757,50035,640763,989Jun 11 04:36 PM
Kauffman MichaelChief Executive OfficerJun 09Option Exercise4.757,50035,640763,989Jun 11 04:39 PM
Kauffman MichaelChief Executive OfficerJun 09Sale18.507,500138,746756,489Jun 11 04:39 PM
Shacham SharonPresident & CSOJun 09Sale18.507,500138,746756,489Jun 11 04:36 PM
Shacham SharonPresident & CSOMay 18Option Exercise0.037,500248763,989May 19 05:34 PM
Kauffman MichaelChief Executive OfficerMay 18Option Exercise0.037,500248763,989May 19 05:36 PM
Kauffman MichaelChief Executive OfficerMay 18Sale20.007,500150,000756,489May 19 05:36 PM
Shacham SharonPresident & CSOMay 18Sale20.007,500150,000756,489May 19 05:34 PM
Shacham SharonPresident & CSOMay 15Option Exercise0.037,500248763,989May 19 05:34 PM
Kauffman MichaelChief Executive OfficerMay 15Option Exercise0.037,500248763,989May 19 05:36 PM
Shacham SharonPresident & CSOMay 15Sale18.657,500139,840756,489May 19 05:34 PM
Kauffman MichaelChief Executive OfficerMay 15Sale18.657,500139,840756,489May 19 05:36 PM
Kauffman MichaelChief Executive OfficerMay 07Option Exercise4.757,50035,640763,989May 11 04:19 PM
Kauffman MichaelChief Executive OfficerMay 07Option Exercise4.757,50035,640562,622May 11 04:19 PM
Shacham SharonPresident & CSOMay 07Option Exercise4.757,50035,640562,622May 11 04:22 PM
Shacham SharonPresident & CSOMay 07Option Exercise4.757,50035,640763,989May 11 04:22 PM
Primiano Christopher BrettEVP, CBO, GC & SecretaryMay 07Option Exercise6.542,94619,2677,595May 11 04:25 PM
Frenkel RanChief Dev Operations OfficerMay 07Sale20.001,97439,48035,088May 11 04:26 PM
Primiano Christopher BrettEVP, CBO, GC & SecretaryMay 07Sale19.739,660190,6274,649May 11 04:25 PM
Shacham SharonPresident & CSOMay 07Sale19.637,500147,209555,122May 11 04:22 PM
Shacham SharonPresident & CSOMay 07Sale19.637,500147,205756,489May 11 04:22 PM
Kauffman MichaelChief Executive OfficerMay 07Sale19.637,500147,205756,489May 11 04:19 PM
Kauffman MichaelChief Executive OfficerMay 07Sale19.637,500147,209555,122May 11 04:19 PM
Shacham SharonPresident & CSOApr 09Option Exercise4.7510,00047,520565,122Apr 10 05:06 PM
Kauffman MichaelChief Executive OfficerApr 09Option Exercise4.7510,00047,520565,122Apr 10 05:09 PM
Kauffman MichaelChief Executive OfficerApr 09Sale20.6410,000206,404555,122Apr 10 05:09 PM
Shacham SharonPresident & CSOApr 09Sale20.6410,000206,404555,122Apr 10 05:06 PM
Shacham SharonPresident & CSOApr 08Option Exercise4.7510,00047,520766,489Apr 10 05:06 PM
Kauffman MichaelChief Executive OfficerApr 08Option Exercise4.7510,00047,520766,489Apr 10 05:09 PM
Kauffman MichaelChief Executive OfficerApr 08Sale18.6110,000186,115756,489Apr 10 05:09 PM
Shacham SharonPresident & CSOApr 08Sale18.6110,000186,115756,489Apr 10 05:06 PM
Greene Barry EDirectorMar 13Option Exercise0.033,0301006,030Mar 17 05:35 PM
Shacham SharonPresident & CSOMar 10Option Exercise4.7510,00047,520565,122Mar 11 07:10 PM
Kauffman MichaelChief Executive OfficerMar 10Option Exercise4.7510,00047,520565,122Mar 11 07:07 PM
Shacham SharonPresident & CSOMar 10Sale22.2210,000222,186555,122Mar 11 07:10 PM
Kauffman MichaelChief Executive OfficerMar 10Sale22.2210,000222,186555,122Mar 11 07:07 PM